Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa: An Open-Label, Randomized, Bayesian Noninferiority Trial

Brogan P. A., Arch B., Hickey H., Anton J., Iglesias E., Baildam E., ...More

ARTHRITIS & RHEUMATOLOGY, vol.73, no.9, pp.1673-1682, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 73 Issue: 9
  • Publication Date: 2021
  • Doi Number: 10.1002/art.41730
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CINAHL, EMBASE, MEDLINE
  • Page Numbers: pp.1673-1682
  • Eskisehir Osmangazi University Affiliated: No


Objective. Cyclophosphamide (CYC) is used in clinical practice off-label for the induction of remission in childhood polyarteritis nodosa (PAN). Mycophenolate mofetil (MMF) might offer a less toxic alternative. This study was undertaken to explore the relative effectiveness of CYC and MMF treatment in a randomized controlled trial (RCT).